Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd (Nasdaq: CMMB) will announce its first quarter 2022 financial results and provide a business update on May 12, 2022, during a conference call at 8:00 am ET. The call will review performance, recent events, and feature a live Q&A session. Chemomab focuses on developing therapeutics for fibrotic and inflammatory diseases, with its CM-101 monoclonal antibody currently in two Phase 2 trials for severe conditions affecting the liver and systemic sclerosis. For further details, visit chemomab.com.
- Chemomab is advancing CM-101 in two Phase 2 trials for serious diseases.
- The upcoming financial results may provide insights into business performance.
- None.
TEL AVIV, Israel, May 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its first quarter 2022 financial results and provide a business update on Thursday, May 12, 2022. The company will host a conference call at 8:00 am Eastern Time, which will be webcast at the link below and on the company's investor relations website.
Chemomab's management team will review first quarter 2022 performance, discuss recent and upcoming events and conduct a live question-and-answer session.
Conference Call and Webcast Information:
Live Webcast at 8:00 am ET, May 12, 2022
Click this Webcast link to access the live webcast or replay.
The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.
By Telephone
Conference call information:
US Investors: +1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference ID: 13728593
Please call 5-10 minutes before the scheduled start time and ask for the Chemomab conference call.
About Chemomab Therapeutics
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 safety and efficacy trials—one in patients with primary sclerosing cholangitis and the second in patients with liver fibrosis, with a third Phase 2 trial in systemic sclerosis expected to begin in 2022.
For more information on Chemomab, visit chemomab.com
Contacts:
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1 (917) 734-7387
ir@chemomab.com
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations,
Strategic Communications
Phone: +1 (917) 355-9234
barbara@chemomab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-first-quarter-2022-financial-results-and-provide-a-business-update-301539391.html
SOURCE Chemomab Therapeutics, Ltd.
FAQ
When will Chemomab Therapeutics report its first quarter 2022 financial results?
What is the focus of Chemomab Therapeutics?
What is CM-101 and what trials is it currently involved in?
What time is the Chemomab conference call on May 12, 2022?
